FDA Approves Paxlovid (nirmatrelvir tablets and ritonavir tablets) for Adult Patients at High Risk ofProgression to Severe COVID-19
May 25, 2023
FDA Approves Posluma (flotufolastat F 18) Injection, First Radiohybrid PSMA-targeted PET ImagingAgent for Prostate Cancer
May 30, 2023May 26, 2023 - Lexicon Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved InpefaTM (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with:
- Heart failure or
- Type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors.
The broad label encompasses heart failure patients across the full range of left ventricular ejection fraction (LVEF), including preserved ejection fraction and reduced ejection fraction, and for patients with or without diabetes.